Loss of nuclear ATRX immunoreactivity or identification of ATRX mutation differentiates IDH mutant astrocytoma from IDH mutant oligodendroglioma (Ikemura et al., 2016). This evidence concerns the gene IDH2 and oligodendroglioma.